UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-60
SponsorNational Heart Centre Singapore

About this trial

Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. However, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\<50-60 years old), while at the other end of the spectrum, there are also patients with multiple CV risk factors but with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology, especially in the field of genomics, metabolomics, and proteomics, have led to exciting developments in our understanding of the development and prevention of CVD and AMI. In this study, the investigators aim to identify novel gene variants associated with the onset of MI in relatively young patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia.Through genomic, metabolomics and proteomics analyses, this may better improve our understanding of the development of CVD and AMI, potentially developing novel preventive measures to reduce the risk or delay the onset as well as tailoring management plans to improve treatment outcomes and reduce adverse events for the patients.

Eligibility criteria

Qualifiers

Adult >21 years old.

Age ≤50 years old irrespective of the presence of CV risk factors* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor* at the time of myocardial infarction, excluding diabetes mellitus

Able to provide informed consent.

Patients who are willing and able to comply with the study visit and procedures.

Disqualifiers

Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.

Prior PAD and Stroke

Female patients who are pregnant

Patients who are non-Asian

Trial design

Treatments tested in this trial

  • Blood Draw

Treatment groups

1,200 Participants
are divided into 2 treatment groups